Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan

Table 2 Endoscopic cure rate

	10 mg group	20 mg group	Modified dose group2	Total
Gastric ulcer1	71.4%	75.0%	50.0%	71.4%
	(15/21)	(9/12)	(1/2)	(25/35)
Duodenal ulcer	66.7%	-	-	66.7%
	(2/3)			(2/3)
Total	70.8%	75.0%	50.0%	71.1%
	(17/24)	(9/12)	(1/2)	(27/38)

¹The 2 patients with “gastric/duodenal ulcer” were included in tabulations for gastric ulcer;

²Modified dose group consisted of 1 patient changing from 10 mg to 20 mg and 1 patient changing from 20 mg to 10 mg.